Cargando…
Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
Recently, immunotherapy based on blocking immune checkpoints with programmed death‐1 (PD‐1) or PD‐ligand 1 (PD‐L1) Abs has been introduced for the treatment of advanced clear cell renal cell carcinoma (ccRCC), especially tumors resistant to vascular endothelial growth factor‐tyrosine kinase inhibito...
Autores principales: | Mikami, Shuji, Mizuno, Ryuichi, Kondo, Tsunenori, Shinohara, Nobuo, Nonomura, Norio, Ozono, Seiichiro, Eto, Masatoshi, Tatsugami, Katsunori, Takayama, Tatsuya, Matsuyama, Hideyasu, Kishida, Takeshi, Oya, Mototsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550131/ https://www.ncbi.nlm.nih.gov/pubmed/30972888 http://dx.doi.org/10.1111/cas.14019 |
Ejemplares similares
-
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021) -
Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
por: Uemura, Motohide, et al.
Publicado: (2021) -
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018) -
Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018) -
A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)